MESO · Mesoblast Limited

Mesoblast Limited has strategically expanded its technology platform by acquiring exclusive worldwide rights to a chimeric antigen receptor (CAR) technology developed at Mayo Clinic. This transaction aligns with the company's strategy to extend its market leadership in allogeneic cellular medicines by creating products with enhanced efficacy and new target indications. The CAR technology is designed to be incorporated into Mesoblast's mesenchymal lineage stromal cell (MSC) products to substantially enhance targeted homing to inflamed tissue, resulting in greater potency. The consideration for the acquisition was structured as the issuance of ASX ordinary shares, which allows the company to secure critical intellectual property without utilizing cash reserves. This is particularly significant for a clinical-stage company focused on R&D. The foundational work, published in Nature Biomedical Engineering, identified CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases. Mesoblast plans to leverage this technology to generate products for ulcerative colitis, Crohn's disease, and Lupus Nephritis. As part of the agreement, Mayo Clinic will provide in-kind support geared toward further advancing the technology, including GMP manufacturing activities, indicating a collaborative effort to accelerate development. This acquisition strengthens Mesoblast's intellectual property portfolio, which extends through at least 2044 in all major markets.